Psychological distress in men with prostate cancer undertaking androgen deprivation therapy: modifying effects of exercise from a year-long randomized controlled trial.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
02
11
2020
accepted:
15
01
2021
revised:
16
12
2020
pubmed:
10
2
2021
medline:
2
2
2022
entrez:
9
2
2021
Statut:
ppublish
Résumé
To assess the long-term effects of various exercise modes on psychological distress in men with prostate cancer on androgen deprivation therapy (ADT). 135 prostate cancer patients aged 43-90 years on ADT were randomized to twice weekly supervised impact loading and resistance exercise (ImpRes), supervised aerobic and resistance exercise (AerRes), and usual care/delayed supervised aerobic exercise (DelAer) for 12 months, and completed measures of psychological distress using the Brief Symptom Inventory-18 (BSI-18). BSI-18 provides three subscales for anxiety, depression, and somatisation, as well as the global severity index (GSI) where higher scores indicate higher distress. Following the intervention, somatization was not different to baseline, however, there were significant interactions (p < 0.01) for depression, anxiety, and the GSI. In ImpRes, depression was reduced at 12 months compared to baseline and 6 months (0.78 ± 1.39 vs. 1.88 ± 3.24 and 1.48 ± 2.65, p < 0.001), as was the GSI (3.67 ± 4.34 vs. 5.94 ± 7.46 and 4.64 ± 4.73, p < 0.001) with anxiety reduced compared to baseline (1.08 ± 1.54 vs. 1.98 ± 2.56). Depression and the GSI decreased (p < 0.05) in AerRes at 6 months but increased by 12 months, while in DelAer the GSI was reduced at 12 months compared to 6 months (3.78 ± 3.94 vs. 5.25 ± 4.22, p = 0.031). Men with the highest level of anxiety, depression, somatization, and the GSI improved the most with exercise (p Various supervised exercise modes (aerobic, resistance and impact loading) are effective in reducing psychological distress in men with prostate cancer on ADT. Those with the highest level of psychological distress improved the most. Supervised exercise should be prescribed to improve psychological health in prostate cancer patients on ADT.
Identifiants
pubmed: 33558661
doi: 10.1038/s41391-021-00327-2
pii: 10.1038/s41391-021-00327-2
pmc: PMC8384619
doi:
Substances chimiques
Androgen Antagonists
0
Banques de données
ANZCTR
['ACTRN12609000200280']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
758-766Informations de copyright
© 2021. The Author(s).
Références
Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.
doi: 10.1016/j.eururo.2014.07.010
Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102:44–7.
doi: 10.1111/j.1464-410X.2008.07539.x
Couper JW, Love AW, Dunai JV, Duchesne GM, Bloch S, Costello AJ, et al. The psychological aftermath of prostate cancer treatment choices: a comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis. Med J Aust. 2009;190(S7):S86–9.
doi: 10.5694/j.1326-5377.2009.tb02477.x
Cheung AS, de Rooy C, Hoermann R, Lim Joon D, Zajac JD, Grossmann M. Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy. Clin Endocrinol. 2017;86:388–94.
doi: 10.1111/cen.13249
Hyde MK, Newton RU, Galvao DA, Gardiner RA, Occhipinti S, Lowe A, et al. Men’s help-seeking in the first year after diagnosis of localised prostate cancer. Eur J Cancer Care. 2017;26:e12497. https://doi.org/10.1111/ecc.12497 .
Thomas HR, Chen MH, D’Amico AV, Bennett CL, Kattan MW, Sartor O, et al. Association between androgen deprivation therapy and patient-reported depression in men with recurrent prostate cancer. Clin Genitourin Cancer 2018;16:313–7.
doi: 10.1016/j.clgc.2018.05.007
Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol. 2016;34:1905–12.
doi: 10.1200/JCO.2015.64.1969
Chambers SK, Foley E, Clutton S, McDowall R, Occhipinti S, Berry M, et al. The role of mindfulness in distress and quality of life for men with advanced prostate cancer. Qual Life Res. 2016;25:3027–35.
doi: 10.1007/s11136-016-1341-3
Klaassen Z, Jen RP, DiBianco JM, Reinstatler L, Li Q, Madi R, et al. Factors associated with suicide in patients with genitourinary malignancies. Cancer. 2015;121:1864–72.
doi: 10.1002/cncr.29274
Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsdottir U, et al. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst. 2010;102:307–14.
doi: 10.1093/jnci/djp537
Prasad SM, Eggener SE, Lipsitz SR, Irwin MR, Ganz PA, Hu JC. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol. 2014;32:2471–8.
doi: 10.1200/JCO.2013.51.1048
Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 2014;4:e003901.
doi: 10.1136/bmjopen-2013-003901
Chambers SK, Hyde MK, Smith DP, Hughes S, Yuill S, Egger S, et al. New challenges in psycho-oncology research III: a systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research implications. Psychooncology. 2017;26:873–913.
doi: 10.1002/pon.4431
Galvao DA, Newton RU, Gardiner RA, Girgis A, Lepore SJ, Stiller A, et al. Compliance to exercise-oncology guidelines in prostate cancer survivors and associations with psychological distress, unmet supportive care needs, and quality of life. Psychooncology. 2015;24:1241–9.
doi: 10.1002/pon.3882
Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. J Psychiatr Res. 2016;77:42–51.
doi: 10.1016/j.jpsychires.2016.02.023
Herring MP, Puetz TW, O’Connor PJ, Dishman RK. Effect of exercise training on depressive symptoms among patients with a chronic illness: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:101–11.
doi: 10.1001/archinternmed.2011.696
Gordon BR, McDowell CP, Hallgren M, Meyer JD, Lyons M, Herring MP. Association of efficacy of resistance exercise training with depressive symptoms: meta-analysis and meta-regression analysis of randomized clinical trials. JAMA Psychiatry. 2018;75:566–76.
doi: 10.1001/jamapsychiatry.2018.0572
Crawford-Williams F, March S, Goodwin BC, Ralph N, Galvao DA, Newton RU, et al. Interventions for prostate cancer survivorship: a systematic review of reviews. Psycho-Oncol. 2018;27:2339–48.
doi: 10.1002/pon.4888
Vashistha V, Singh B, Kaur S, Prokop LJ, Kaushik D. The effects of exercise on fatigue, quality of life, and psychological function for men with prostate cancer: systematic review and meta-analyses. Eur Urol Focus. 2016;2:284–95.
doi: 10.1016/j.euf.2016.02.011
Taaffe DR, Newton RU, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol. 2017;72:293–9.
doi: 10.1016/j.eururo.2017.02.019
Newton RU, Galvao DA, Spry N, Joseph D, Chambers SK, Gardiner RA, et al. Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients. Med Sci Sport Exer. 2019;51:607–14.
doi: 10.1249/MSS.0000000000001831
Wall BA, Galvao DA, Fatehee N, Taaffe DR, Spry N, Joseph D, et al. Exercise improves (V)over dotO(2max) and body composition in androgen deprivation therapy-treated prostate cancer patients. Med Sci Sport Exer. 2017;49:1503–10.
doi: 10.1249/MSS.0000000000001277
Newton RU, Taaffe DR, Spry N, Gardiner RA, Levin G, Wall B, et al. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC Cancer. 2009;9:210.
doi: 10.1186/1471-2407-9-210
Derogatis L. BSI 18: Brief Symptom Inventory 18: Administration, Scoring, and Procedure Manual. Minneapolis, MN: NCS Pearson; 2001.
Zabora J, BrintzenhofeSzoc K, Jacobsen P, Curbow B, Piantadosi S, Hooker C, et al. A new psychosocial screening instrument for use with cancer patients. Psychosomatics. 2001;42:241–6.
doi: 10.1176/appi.psy.42.3.241
Recklitis CJ, Rodriguez P. Screening childhood cancer survivors with the brief symptom inventory-18: classification agreement with the symptom checklist-90-revised. Psychooncology. 2007;16:429–36.
doi: 10.1002/pon.1069
Franke GH, Jaeger S, Glaesmer H, Barkmann C, Petrowski K, Braehler E. Psychometric analysis of the brief symptom inventory 18 (BSI-18) in a representative German sample. BMC Med Res Methodol. 2017;17:14.
doi: 10.1186/s12874-016-0283-3
Galvao DA, Newton RU, Gardiner RA, Girgis A, Lepore SJ, Stiller A, et al. Compliance to exercise-oncology guidelines in prostate cancer survivors and associations with psychological distress, unmet supportive care needs, and quality of life. Psycho-Oncol. 2015;24:1241–9.
doi: 10.1002/pon.3882
Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28:340–7.
doi: 10.1200/JCO.2009.23.2488
Craft LL, Vaniterson EH, Helenowski IB, Rademaker AW, Courneya KS. Exercise effects on depressive symptoms in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2012;21:3–19.
doi: 10.1158/1055-9965.EPI-11-0634
Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev. 2017;52:91–104.
doi: 10.1016/j.ctrv.2016.11.010
Lopez P, Taaffe DR, Newton RU, Spry N, Shannon T, Frydenberg M, et al. Can exercise adaptations be maintained in men with prostate cancer following supervised programmes? Implications to the COVID-19 landscape of urology and clinical exercise. Eur Urol Open Sci. 2020;21:47–50.
doi: 10.1016/j.euros.2020.09.002
Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J. The validity of the distress thermometer in prostate cancer populations. Psychooncology 2014;23:195–203.
doi: 10.1002/pon.3391
Chambers SK, Galvão DA, Green A, Lazenby M, Newton RU, Oliffe JL, et al. A psychosocial care model for men with prostate cancer. Australia: Prostate Cancer Foundation of Australia and University of Technology Sydney; 2019.
Dunn J, Green A, Ralph N, Newton RU, Kneebone A, Frydenberg M, et al. Prostate cancer survivorship essentials framework: guidelines for practitioners. BJU Int. 2020.
Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27:344–51.
doi: 10.1200/JCO.2007.15.4963
Galvao DA, Taaffe DR, Spry N, Newton RU. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis. 2007;10:340–6.
doi: 10.1038/sj.pcan.4500975
Lopez P, Taaffe DR, Newton RU, Buffart LM, Galvão DA. What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes. Prostate Cancer Prostatic Dis. 2020. https://doi.org/10.1038/s41391-020-00301-4. Epub ahead of print.
Schmitz KH, Campbell AM, Stuiver MM, Pinto BM, Schwartz AL, Morris GS, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA Cancer J Clin. 2019;69:468–84.
doi: 10.3322/caac.21579